Home Blog of Signal Transduction Proteases MMP Astaxanthin: A Marine Drug That Ameliorates Cerebrovascular-Damage-Associated Alzheimer's Disease in a Zebrafish Model via the Inhibition of Matrix Metalloprotease-13

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

Astaxanthin: A Marine Drug That Ameliorates Cerebrovascular-Damage-Associated Alzheimer's Disease in a Zebrafish Model via the Inhibition of Matrix Metalloprotease-13

Alzheimer's disease (AD) is a major type of dementia disorder. Common cognitive changes occur as a result of cerebrovascular damage (CVD) via the disruption of matrix metalloproteinase-13 (MMP-13). In diabetic cases, the progress of vascular dementia is faster and the AD rate is higher. Patients with type 2 diabetes are known to have a higher risk of the factor for AD progression. Hence, this study is designed to investigate the role of astaxanthin (AST) in CVD-associated AD in zebrafish via the inhibition of MMP-13 activity. CVD was developed through the intraperitoneal and intracerebral injection of streptozotocin (STZ). The AST (10 and 20 mg/L), donepezil (1 mg/L), and MMP-13 inhibitor (i.e., CL-82198; 10 μM) were exposed for 21 consecutive days in CVD animals. The cognitive changes in zebrafish were evaluated through light and dark chamber tests, a color recognition test, and a T-maze test. The biomarkers of AD pathology were assessed via the estimation of the cerebral extravasation of Evans blue, tissue nitrite, amyloid beta-peptide aggregation, MMP-13 activity, and acetylcholinesterase activity. The results revealed that exposure to AST leads to ameliorative behavioral and biochemical changes. Hence, AST can be used for the management of AD due to its multi-targeted actions, including MMP-13 inhibition.

 

Comments:

This study sounds fascinating! It seems to focus on the potential role of astaxanthin in mitigating cognitive and biochemical changes associated with Alzheimer's disease in zebrafish, particularly through MMP-13 inhibition in cerebrovascular damage.

Astaxanthin's ability to target multiple aspects of AD pathology, including MMP-13 inhibition, is intriguing. The use of zebrafish as a model organism offers several advantages in studying neurological disorders due to their genetic similarity to humans and the ease of observing behavioral changes.

The study's multi-tiered approach, encompassing behavioral tests like the light and dark chamber, color recognition, and T-maze tests along with biochemical assessments of AD pathology markers, provides a comprehensive understanding of astaxanthin's effects.

Given the known association between diabetes and increased risk for AD progression, investigating interventions like astaxanthin becomes even more critical, especially if it demonstrates efficacy in managing cerebrovascular damage and MMP-13 activity.

If this study's findings hold up in further research, astaxanthin could potentially emerge as a promising therapeutic option for managing Alzheimer's disease by targeting MMP-13 and associated cerebrovascular damage.

Related Products

Cat.No. Product Name Information
E0073 CL-82198 CL-82198 is a selective, orally bioavailable MMP-13 inhibitor with an IC50 of 3.2 μM.

Related Targets

MMP